Altamira Therapeutics (CYTO) Short Interest Ratio & Short Volume → Biden’s $374B Giveaway Into This Sector (From DTI) (Ad) Free CYTO Stock Alerts $1.50 +0.02 (+1.35%) (As of 04/18/2024 ET) Add Compare Share Share Short InterestStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Altamira Therapeutics Short Interest DataCurrent Short Volume444,500 sharesPrevious Short Volume61,700 sharesChange Vs. Previous Month+620.42%Dollar Volume Sold Short$920,115.00Short Interest Ratio / Days to Cover0.4Last Record DateMarch 31, 2024Outstanding Shares1,580,000 sharesFloat Size1,580,000 sharesShort Percent of Float28.13%Today's Trading Volume23,428 sharesAverage Trading Volume1,002,880 sharesToday's Volume Vs. Average2% Short Selling Altamira Therapeutics ? Sign up to receive the latest short interest report for Altamira Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatCYTO Short Interest Over TimeCYTO Days to Cover Over TimeCYTO Percentage of Float Shorted Over Time Ad InvestorPlaceNow Open: Crypto emergency updateDuring the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.Just click here to sign up and be among the first to get it. Altamira Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/31/2024444,500 shares $920,115.00 +620.4%28.1%0.4 $2.07 3/15/202461,700 shares $106,741.00 +9.0%3.9%0.1 $1.73 2/29/202456,600 shares $106,408.00 -6.3%3.6%0.2 $1.88 2/15/202460,400 shares $112,948.00 -13.7%3.8%0.1 $1.87 1/31/202470,000 shares $129,500.00 +75.9%N/A0.1 $1.85 1/15/202439,800 shares $107,858.00 -29.1%N/A0 $2.71 Get the Latest News and Ratings for CYTO and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Altamira Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 12/31/202356,100 shares $195,228.00 -68.0%N/A0.1 $3.48 12/15/2023175,400 shares $650,734.00 -69.3%N/A0.2 $3.71 11/30/2023570,500 shares $223,179.60 +10.9%N/A0 $0.39 11/15/2023514,300 shares $50,915.70 +181.5%N/A0.1 $0.10 10/31/2023182,700 shares $27,003.06 +43.5%N/A0.2 $0.15 10/15/2023127,300 shares $30,233.75 +5.5%N/A0.3 $0.24 9/30/2023120,700 shares $29,511.15 +88.3%N/A0.4 $0.24 9/15/202364,100 shares $16,986.50 +33.5%N/A0.2 $0.27 8/31/202348,000 shares $17,275.20 -77.2%N/A0.2 $0.36 8/15/2023210,600 shares $80,028.00 -67.4%N/A0.4 $0.38 7/31/2023646,300 shares $245,594.00 +69.8%N/A1.1 $0.38 7/15/2023380,600 shares $146,911.60 +319.2%N/A0.3 $0.39 6/30/202390,800 shares $58,202.80 -16.5%N/A0 $0.64 6/15/2023108,700 shares $90,221.00 -47.4%N/A0 $0.83 5/31/2023206,600 shares $171,478.00 +140.0%N/A0.1 $0.83 5/15/202386,100 shares $80,572.38 -9.9%N/A0 $0.94 4/30/202395,600 shares $91,776.00 -92.0%N/A0 $0.96 4/15/20231,200,000 shares $1.36 million +253.5%N/A0.7 $1.13 3/31/2023339,500 shares $434,560.00 +5.1%31.2%0.3 $1.28 3/15/2023323,100 shares $429,723.00 +1,240.7%29.6%0.6 $1.33 2/28/202324,100 shares $57,840.00 +61.7%2.2%0.1 $2.40 2/15/202314,900 shares $39,336.00 +86.3%1.3%0.4 $2.64 1/31/20238,000 shares $22,080.00 -57.5%0.7%0.2 $2.76 1/15/202318,800 shares $97,760.00 -49.9%1.7%0.2 $5.20 12/30/202237,500 shares $181,875.00 +73.6%3.4%0.3 $4.85 12/15/202221,600 shares $110,160.00 -18.5%2.1%0.2 $5.10 11/30/202226,500 shares $149,725.00 +16.7%2.6%0.3 $5.65 11/15/202222,700 shares $130,525.00 -76.7%2.2%0.2 $5.75 10/31/202297,400 shares $728,552.00 +435.2%9.7%1 $7.48 10/15/202218,200 shares $107,452.80 -95.1%0.1%0.2 $5.90 9/30/2022371,000 shares $107,552.90 +69.2%2.6%0.3 $0.29 9/15/2022219,300 shares $85,066.47 -57.5%1.5%0.2 $0.39 8/31/2022516,300 shares $188,965.80 +17.0%3.5%0.4 $0.37 8/15/2022441,300 shares $216,237.00 -46.7%3.0%0.3 $0.49New crypto project uncovers 2,050% in 65 days (Ad)During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.Just click here to sign up and be among the first to get it. CYTO Short Interest - Frequently Asked Questions What is Altamira Therapeutics' current short interest? Short interest is the volume of Altamira Therapeutics shares that have been sold short but have not yet been covered or closed out. As of March 31st, investors have sold 444,500 shares of CYTO short. 28.13% of Altamira Therapeutics' shares are currently sold short. Learn More on Altamira Therapeutics' current short interest. Which institutional investors are shorting Altamira Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Altamira Therapeutics: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Altamira Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 28.13% of Altamira Therapeutics' floating shares are currently sold short. Is Altamira Therapeutics' short interest increasing or decreasing? Altamira Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 444,500 shares, an increase of 620.4% from the previous total of 61,700 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Altamira Therapeutics' float size? Altamira Therapeutics currently has issued a total of 1,580,000 shares. Some of Altamira Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Altamira Therapeutics currently has a public float of 1,580,000 shares. How does Altamira Therapeutics' short interest compare to its competitors? 28.13% of Altamira Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Altamira Therapeutics: Sonoma Pharmaceuticals, Inc. (0.19%), Agile Therapeutics, Inc. (12.68%), Onconetix, Inc. (3.17%), CohBar, Inc. (0.59%), CNS Pharmaceuticals, Inc. (0.49%), TransCode Therapeutics, Inc. (0.61%), Cyclacel Pharmaceuticals, Inc. (2.03%), Aravive, Inc. (1.81%), Notable Labs, Ltd. (0.05%), Salarius Pharmaceuticals, Inc. (6.72%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: TC Energy Co. ($4.49 billion), T-Mobile US, Inc. ($3.94 billion), General Motors ($3.34 billion), Charter Communications, Inc. ($3.32 billion), Occidental Petroleum Co. ($3.21 billion), Super Micro Computer, Inc. ($3.13 billion), Coinbase Global, Inc. ($3.08 billion), Moderna, Inc. ($2.28 billion), Tractor Supply ($2.24 billion), and Royal Caribbean Cruises Ltd. ($2.14 billion). View all of the most shorted stocks. What does it mean to sell short Altamira Therapeutics stock? Short selling CYTO is an investing strategy that aims to generate trading profit from Altamira Therapeutics as its price is falling. CYTO shares are trading up $0.02 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Altamira Therapeutics? A short squeeze for Altamira Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of CYTO, which in turn drives the price of the stock up even further. How often is Altamira Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CYTO, twice per month. The most recent reporting period available is March, 31 2024. More Short Interest Resources from MarketBeat Related Companies: Sonoma Pharmaceuticals Short Interest Agile Therapeutics Short Interest Onconetix Short Interest CohBar Short Interest CNS Pharmaceuticals Short Interest TransCode Therapeutics Short Interest Cyclacel Pharmaceuticals Short Interest Aravive Short Interest Notable Labs Short Interest Salarius Pharmaceuticals Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:CYTO) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingBiden’s $374B Giveaway Into This SectorDTIForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThe #1 Crypto for 2024InvestorPlaceHe Is Giving Away BitcoinCrypto Swap ProfitsHow Biden has already won 2024Porter & CompanyMan Who Predicted 2008: “This Will be Worse.”AltimetryOptions trading has suddenly become more reliable.Eagle Publishing